Status:
COMPLETED
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Collaborating Sponsors:
Merck Serono Limited, UK
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) and is one of the most common causes of neurological disability in young adults. Rebif is ...
Eligibility Criteria
Inclusion
- Have relapsing remitting multiple sclerosis and currently receiving Rebif treatment and using the Rebiject II injection device
- Be under regular review by a MS nurse
- Be aged 18 or above
- Be willing and able to participate in the trial and to have provided written informed consent
Exclusion
- Receiving disease modifying therapy other than Rebif
- Receiving Rebif but not using the Rebiject II injection device
- Do not self inject
- Are unable or unwilling to provide informed consent
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01195857
Start Date
January 1 2009
End Date
September 1 2009
Last Update
February 4 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.